Cancer Research and Treatment

Original Articles

Genitourinary Cancer

A Predictive Model Based on Bi-parametric Magnetic Resonance Imaging and Clinical Parameters for Clinically Significant Prostate Cancer in the Korean Population: Tae Il Noh, Chang Wan Hyun, Ha Eun Kang, Hyun Jung Jin, Jong Hyun Tae, Ji Sung Shim, Sung Gu Kang, Deuk Jae Sung, Jun Cheon, Jeong Gu Lee, Seok Ho Kang; Cancer Res Treat. 2021;53(4):1148-1155. Published online December 31, 2020; DOI: https://doi.org/10.4143/crt.2020.1068

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to develop and validate a predictive model for the assessment of clinically significant prostate cancer (csPCa) in men, prior to prostate biopsies, based on bi-parametric magnetic resonance imaging (bpMRI) and clinical parameters.
Materials and Methods
We retrospectively analyzed 300 men with clinical suspicion of prostate cancer (prostate-specific antigen [PSA] ≥ 4.0 ng/mL and/or abnormal findings in a digital rectal examination), who underwent bpMRI-ultrasound fusion transperineal targeted and systematic biopsies in the same session, at a Korean university hospital. Predictive models, based on Prostate Imaging Reporting and Data Systems scores of bpMRI and clinical parameters, were developed to detect csPCa (intermediate/high grade [Gleason score ≥ 3+4]) and compared by analyzing the areas under the curves and decision curves.
Results
A predictive model defined by the combination of bpMRI and clinical parameters (age, PSA density) showed high discriminatory power (area under the curve, 0.861) and resulted in a significant net benefit on decision curve analysis. Applying a probability threshold of 7.5%, 21.6% of men could avoid unnecessary prostate biopsy, while only 1.0% of significant prostate cancers were missed.
Conclusion
This predictive model provided a reliable and measurable means of risk stratification of csPCa, with high discriminatory power and great net benefit. It could be a useful tool for clinical decision-making prior to prostate biopsies.

Citations

Citations to this article as recorded by

Abbreviated MRI Protocols in the Abdomen and Pelvis
Kristina I. Ringe, Jin Wang, Ying Deng, Shan Pi, Amine Geahchan, Bachir Taouli, Mustafa R. Bashir
Journal of Magnetic Resonance Imaging.2024; 59(1): 58. CrossRef
Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer
Arya Haj-Mirzaian, Kristine S. Burk, Ronilda Lacson, Daniel I. Glazer, Sanjay Saini, Adam S. Kibel, Ramin Khorasani
JAMA Network Open.2024; 7(3): e244258. CrossRef
The Barcelona Predictive Model of Clinically Significant Prostate Cancer
Juan Morote, Angel Borque-Fernando, Marina Triquell, Anna Celma, Lucas Regis, Manel Escobar, Richard Mast, Inés M. de Torres, María E. Semidey, José M. Abascal, Carles Sola, Pol Servian, Daniel Salvador, Anna Santamaría, Jacques Planas, Luis M. Esteban, E
Cancers.2022; 14(6): 1589. CrossRef
Efficacy of Tadalafil in Penile Rehabilitation Started Before Nerve-Sparing Robot-Assisted Radical Prostatectomy: A Double-Blind Pilot Study
Tae Il Noh, Ji Sung Shim, Sung Gu Kang, Jun Cheon, Jeong Gu Lee, Seok Ho Kang
Sexual Medicine.2022; 10(3): 1. CrossRef
Comparative Analysis of PSA Density and an MRI-Based Predictive Model to Improve the Selection of Candidates for Prostate Biopsy
Juan Morote, Angel Borque-Fernando, Marina Triquell, Anna Celma, Lucas Regis, Richard Mast, Inés M. de Torres, María E. Semidey, José M. Abascal, Pol Servian, Anna Santamaría, Jacques Planas, Luis M. Esteban, Enrique Trilla
Cancers.2022; 14(10): 2374. CrossRef
Magnetic Resonance Imaging-Based Predictive Models for Clinically Significant Prostate Cancer: A Systematic Review
Marina Triquell, Miriam Campistol, Ana Celma, Lucas Regis, Mercè Cuadras, Jacques Planas, Enrique Trilla, Juan Morote
Cancers.2022; 14(19): 4747. CrossRef

6,855 View
166 Download
5 Web of Science
6 Crossref

Diagnostic Accuracy and Value of Magnetic Resonance Imaging–Ultrasound Fusion Transperineal Targeted and Template Systematic Prostate Biopsy Based on Bi-parametric Magnetic Resonance Imaging: Tae Il Noh, Jong Hyun Tae, Hyung Keun Kim, Ji Sung Shim, Sung Gu Kang, Deuk Jae Sung, Jun Cheon, Jeong Gu Lee, Seok Ho Kang; Cancer Res Treat. 2020;52(3):714-721. Published online February 10, 2020; DOI: https://doi.org/10.4143/crt.2019.716

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to investigate the diagnostic value of magnetic resonance imaging (MRI)–ultrasound (US) fusion transperineal targeted biopsy (FTB) and fusion template systematic biopsy (FSB) for prostate cancer (PCa) and clinically significant prostate cancer (csPCa) (intermediate/high grade [Gleason score ≥ 3+4]) based on bi-parametric MRI (bpMRI).
Materials and methods
Retrospectively, we analyzed 300 patients with elevated prostate-specific antigen (≥ 4.0 ng/mL) and/or abnormal findings in a digital rectal examination at the Korea University Hospital. All 300 men underwent bpMRI-US fusion transperineal FTB and FSB in the period from April 2017 to March 2019.
Results
PCas were detected in 158 of 300 men (52.7%), and the prevalence of csPCa was 34.0%. CsPCas were detected in 12 of 102 (11.8%) with Prostate Imaging-Reporting and Data System (PI-RADS) 3, 42 of 92 (45.7%) with PI-RADS 4, respectively; and 45 of 62 (72.6%) men with PI-RADS 5, respectively. BpMRI showed a sensitivity of 95.1% and negative predictive value of 89.6% for csPCa. FTB detected additional csPCa in 33 men (12.9%) compared to FSB. Compared to FTB, FSB detected additional csPCa in 10 men (3.9%).
Conclusion
BpMRI-US FTB and FSB improved detection of PCa and csPCa. The accuracy of bi-parametric MRI is comparable with that of multi-parametric MRI. Further, it is rapid, simpler, cheaper, and no side effects of contrast media. Therefore, it is expected that bpMRI-US transperineal FTB and FSB could be a good alternative to conventional US-guided transrectal biopsy, which is the current gold standard.

Citations

Citations to this article as recorded by

Fusion MRI/Ultrasound-Guided Transperineal Biopsy: A Game Changer in Prostate Cancer Diagnosis
Ilias Giannakodimos, Aris Kaltsas, Napoleon Moulavasilis, Zisis Kratiras, Dionysios Mitropoulos, Michael Chrisofos, Konstantinos Stravodimos, Evangelos Fragkiadis
Journal of Clinical Medicine.2025; 14(2): 453. CrossRef
Rapid diagnostic pathways for prostate cancer: A realist synthesis
Katie Jones, Arya Chandran, Jaynie Rance
Journal of Cancer Policy.2024; 42: 100514. CrossRef
Diagnostic performance of transperineal prostate targeted biopsy alone according to the PI-RADS score based on bi-parametric magnetic resonance imaging
Tae Il Noh, Ji Sung Shim, Seok Ho Kang, Jun Cheon, Sung Gu Kang
Frontiers in Oncology.2023;[Epub] CrossRef
Efficacy of Tadalafil in Penile Rehabilitation Started Before Nerve-Sparing Robot-Assisted Radical Prostatectomy: A Double-Blind Pilot Study
Tae Il Noh, Ji Sung Shim, Sung Gu Kang, Jun Cheon, Jeong Gu Lee, Seok Ho Kang
Sexual Medicine.2022; 10(3): 1. CrossRef
Concordance between biparametric MRI, transperineal targeted plus systematic MRI-ultrasound fusion prostate biopsy, and radical prostatectomy pathology
Tae Il Noh, Ji Sung Shim, Sung Gu Kang, Jun Cheon, Jeong Gu Lee, Jeong Hyeon Lee, Seok Ho Kang
Scientific Reports.2022;[Epub] CrossRef
Three-dimensional ultrasound integrating nomogram and the blood flow image for prostate cancer diagnosis and biopsy: A retrospective study
Dong Chen, Yingjie Niu, Haitao Chen, Dequan Liu, Rong Guo, Nan Yao, Zhiyao Li, Xiaomao Luo, Hongyang Li, Shicong Tang
Frontiers in Oncology.2022;[Epub] CrossRef
Comparison between biparametric and multiparametric MRI in predicting muscle invasion by bladder cancer based on the VI-RADS
Tae Il Noh, Ji Sung Shim, Sung Gu Kang, Deuk Jae Sung, Jun Cheon, Ki Choon Sim, Seok Ho Kang
Scientific Reports.2022;[Epub] CrossRef
A Predictive Model Based on Bi-parametric Magnetic Resonance Imaging and Clinical Parameters for Clinically Significant Prostate Cancer in the Korean Population
Tae Il Noh, Chang Wan Hyun, Ha Eun Kang, Hyun Jung Jin, Jong Hyun Tae, Ji Sung Shim, Sung Gu Kang, Deuk Jae Sung, Jun Cheon, Jeong Gu Lee, Seok Ho Kang
Cancer Research and Treatment.2021; 53(4): 1148. CrossRef
PSA Based Biomarkers, Imagistic Techniques and Combined Tests for a Better Diagnostic of Localized Prostate Cancer
Vlad Cristian Munteanu, Raluca Andrada Munteanu, Diana Gulei, Vlad Horia Schitcu, Bogdan Petrut, Ioana Berindan Neagoe, Patriciu Achimas Cadariu, Ioan Coman
Diagnostics.2020; 10(10): 806. CrossRef

7,495 View
169 Download
11 Web of Science
9 Crossref

Poor Preoperative Glycemic Control Is Associated with Dismal Prognosis after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Korean Multicenter Study: Sung Gu Kang, Eu Chang Hwang, Seung Il Jung, Ho Song Yu, Ho Seok Chung, Taek Won Kang, Dong Deuk Kwon, Jun Eul Hwang, Jun Seok Kim, Joon Hwa Noh, Jae Hyung You, Myung Ki Kim, Tae Hoon Oh, Ill Young Seo, Seung Baik, Chul-Sung Kim, Seok Ho Kang, Jun Cheon; Cancer Res Treat. 2016;48(4):1293-1301. Published online March 23, 2016; DOI: https://doi.org/10.4143/crt.2016.021

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to evaluate the effect of diabetes mellitus (DM) and preoperative glycemic control on prognosis in Korean patients with upper tract urothelial carcinoma (UTUC) who underwent radical nephroureterectomy (RNU). Materials and Methods A total of 566 patients who underwent RNU at six institutions between 2004 and 2014 were reviewed retrospectively. Kaplan-Meier and Cox regression analyses were performed to assess the association between DM, preoperative glycemic control, and recurrence-free, cancer-specific, and overall survival.
Results
The median follow-up period was 33.8 months (interquartile range, 41.4 months). A total of 135 patients (23.8%) had DM and 67 patients (11.8%) had poor preoperative glycemic control. Patients with poor preoperative glycemic control had significantly shorter median recurrence-free, cancer-specific, and overall survival than patients with good preoperative glycemic control and non-diabetics (all, p=0.001). In multivariable Cox regression analysis, DM with poor preoperative glycemic control showed association with worse recurrence-free survival (hazard ratio [HR], 2.26; 95% confidence interval [CI], 1.31 to 3.90; p=0.003), cancer-specific survival (HR, 2.96; 95% CI, 1.80 to 4.87; p=0.001), and overall survival (HR, 2.13; 95% CI, 1.40 to 3.22; p=0.001). Conclusion Diabetic UTUC patients with poor preoperative glycemic control had significantly worse oncologic outcomes than diabetic UTUC patients with good preoperative glycemic control and non-diabetics. Further investigation is needed to elucidate the exact mechanism underlying the impact of glycemic control on UTUC treatment outcome.

Citations

Citations to this article as recorded by

Identifying ways to improve diabetes management during cancer treatments (INDICATE): protocol for a qualitative interview study with patients and clinicians
Laura Ashley, Saifuddin Kassim, Ian Kellar, Lisa Kidd, Frances Mair, Mike Matthews, Mollie Price, Daniel Swinson, Johanna Taylor, Galina Velikova, Jonathan Wadsley
BMJ Open.2022; 12(2): e060402. CrossRef
Annular-shaped stenosis in the ureter: Caution should be taken
Jie Ming, Yue Wang, Ziliang Su, Chunyang Wang
Urologic Oncology: Seminars and Original Investigations.2022; 40(6): 274.e7. CrossRef
Glycosylated haemoglobin and prognosis in 10,536 people with cancer and pre-existing diabetes: a meta-analysis with dose-response analysis
Suping Ling, Michael Sweeting, Francesco Zaccardi, David Adlam, Umesh T. Kadam
BMC Cancer.2022;[Epub] CrossRef
Malnutrition management of hospitalized patients with diabetes/hyperglycemia and cancer cachexia
Rosa Burgos Peláez, José Pablo Suárez Llanos, Jose Manuel García Almeida, Pilar Matía Martín, Samara Palma Milla, Alejandro Sanz Paris, Ana Zugasti Murillo, Ana Artero-Fullana, Alfonso Calañas Continente, M.ª Jesús Chinchetru, Katherine García Malpartida,
Nutrición Hospitalaria.2022;[Epub] CrossRef
The Impact of Diabetes on the Prognosis of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy: A Systematic Review and Meta-Analysis
Xiaoshuai Gao, Liang Zhou, Jianzhong Ai, Wei Wang, Xingpeng Di, Liao Peng, Banghua Liao, Xi Jin, Hong Li, Kunjie Wang
Frontiers in Oncology.2021;[Epub] CrossRef
The Prognostic Value of Lymphovascular Invasion in Patients With Upper Tract Urinary Carcinoma After Surgery: An Updated Systematic Review and Meta-Analysis
Lijin Zhang, Bin Wu, Zhenlei Zha, Hu Zhao, Jun Yuan, Yejun Feng
Frontiers in Oncology.2020;[Epub] CrossRef
The impact of preoperative glycated hemoglobin levels on outcomes in oral squamous cell carcinoma
Ze Yun Tay, Huang‐Kai Kao, Kuang‐Hsu Lien, Shao‐Yu Hung, Yenlin Huang, Ngan‐Ming Tsang, Kai‐Ping Chang
Oral Diseases.2020; 26(7): 1449. CrossRef

10,981 View
121 Download
8 Web of Science
7 Crossref

Oncologic and Functional Outcomes after Partial Nephrectomy Versus Radical Nephrectomy in T1b Renal Cell Carcinoma: A Multicenter, Matched Case-Control Study in Korean Patients: Hoon Ah Jang, Jin Wook Kim, Seok Soo Byun, Sung Hoo Hong, Young Jun Kim, Young Hyun Park, Kyung Suk Yang, Seok Cho, Jun Cheon, Seok Ho Kang; Cancer Res Treat. 2016;48(2):612-620. Published online June 5, 2015; DOI: https://doi.org/10.4143/crt.2014.122

Abstract PDF PubReader ePub

Purpose
The study was to compare the oncologic and functional outcomes of partial nephrectomy (PN) and radical nephrectomy (RN) for pathologically proven T1b renal cell carcinoma using pair-matched groups.
Materials and Methods
We reviewed our prospectively maintained database for RN and PN in T1b renal tumors surgically treated between 1999 and 2011 at five institutions in Korea. Of 611 patients treated with PN or RN for a solitary and NX/N0 M0 renal mass (4-7 cm), 577 (PN, 100; RN, 477) patients with pathologically confirmed pT1b remained for analysis. Study subjects were grouped by PN or RN, then matched by age, sex, comorbidities, body mass index, tumor size and depth, histologic type, and preoperative estimated glomerular filtration rate (eGFR) using propensities score. To evaluate oncologic outcomes, overall survival (OS), cancer- specific survival (CSS), and progression-free survival (PFS) rates were analyzed. The functional outcomes were evaluated by postoperative eGFR.
Results
The median follow-up in the RN group was 48.1 and 42.6 months in the PN group. The estimated 10-year CSS rate (PN 85.7% vs. RN 84.4%, p=0.52) and 5- and estimated 10-year PFS rates (PN: 86.4% and 79.2% vs. RN: 86.0% and 66.1%, p=0.66) did not differ significantly between groups. The estimated 10-year OS rate was significantly higher in the PN group (85.7%) compared to the RN group (73.3%) (p=0.003). PN was less likely to induce new-onset chronic kidney disease (CKD) and end-stage CKD compared with RN.
Conclusion
Our study suggests that patients treated with PN demonstrate a superior OS rate and postoperative renal function with analogous CSS and PFS rates compared with pair-matched patients treated with RN.

Citations

Citations to this article as recorded by

Prediction of clinically significant recurrence after partial nephrectomy. Data from the Cancer Registry of Norway with more than five years of follow-up
Ovidiu S. Barnoiu, Tom B. Johannesen, Lien M. Diep, Eskil S. Pedersen, Karin M. Hjelle, Christian Beisland
Scandinavian Journal of Urology.2024; 59: 1. CrossRef
Comparison of Oncological and Functional Outcomes of Radical Versus Partial Nephrectomy for cT1b Renal Cell Carcinoma: A Two-Centre, Matched Analysis
Luna van den Brink, Daniel L. van den Kroonenberg, Niels M. Graafland, Axel Bex, Harrie P. Beerlage, Jeroen R.A. van Moorselaar, Patricia J. Zondervan
Kidney Cancer.2024; 8(1): 51. CrossRef
Differences in the treatment patterns of small renal masses: A disaggregated analyses by race/ethnicity
Samuel Carbunaru, Jordan M. Rich, Yassamin Neshatvar, Katie Murray, Madhur Nayan
Urologic Oncology: Seminars and Original Investigations.2024; 42(12): 453.e1. CrossRef
Three-dimensional visualization techniques improve surgical Decision Making of robotic-assisted partial nephrectomy
Yuchao Wang, Qiliang Teng, Zhihong Dai, Chunyu Chen, Liren Zhang, Jiaxin Xie, Hao Wang, Zihan Xin, Sishan Chen, Yu Tai, Liang Wang, Bo Fan, Zhiyu Liu
Heliyon.2024; 10(21): e38806. CrossRef
Renal functional and cardiovascular outcomes of partial nephrectomy versus radical nephrectomy for renal tumors: a systematic review and meta-analysis
Mario Ochoa-Arvizo, Mariano García-Campa, Karla M. Santos-Santillana, Tobias Klatte, Luis R. García-Chairez, Alejandro D. González-Colmenero, Rigoberto Pallares-Méndez, Daniel E. Cervantes-Miranda, Hiram H. Plata-Huerta, Rene- Rodriguez-Gutierrez, Adrián
Urologic Oncology: Seminars and Original Investigations.2023; 41(3): 113. CrossRef
Frequency of Benign Lesions in Radiologically Presumed Renal Cell Carcinoma Taking Histopathology as Gold Standard
Ayesha Khan, Asad Shahzad Hassan, Naseem Akhtar, Rashid Ali, Rehan Mohsin, Altaf Hashmi, Nazish Mughal
Pakistan Journal of Health Sciences.2023; : 51. CrossRef
Laparoscopic partial versus radical nephrectomy for localized renal cell carcinoma over 4 cm
Zi-Jun Sun, Feng Liu, Hai-Bin Wei, Da-Hong Zhang
Journal of Cancer Research and Clinical Oncology.2023; 149(20): 17837. CrossRef
Long-term oncological results of surgical treatment of localized renal tumors
S. A. Rakul, K. V. Pozdnyakov, R. A. Eloev
Cancer Urology.2022; 17(4): 27. CrossRef
Near-Infrared Fluorescence Imaging of Renal Cell Carcinoma with ASP5354 in a Mouse Model for Intraoperative Guidance
Katsunori Teranishi
International Journal of Molecular Sciences.2022; 23(13): 7228. CrossRef
Comparison of oncologic outcomes between elective partial and radical nephrectomy in patients with renal cell carcinoma in CT1B stadium
Predrag Maric, Predrag Aleksic, Branko Kosevic, Mirko Jovanovic, Vladimir Bancevic, Dejan Simic, Nemanja Rancic
Vojnosanitetski pregled.2022; 79(6): 591. CrossRef
Machine learning-based prediction model for late recurrence after surgery in patients with renal cell carcinoma
Hyung Min Kim, Seok-Soo Byun, Jung Kwon Kim, Chang Wook Jeong, Cheol Kwak, Eu Chang Hwang, Seok Ho Kang, Jinsoo Chung, Yong-June Kim, Yun-Sok Ha, Sung-Hoo Hong
BMC Medical Informatics and Decision Making.2022;[Epub] CrossRef
Comparison of the oncological, perioperative and functional outcomes of partial nephrectomy versus radical nephrectomy for clinical T1b renal cell carcinoma: A systematic review and meta-analysis of retrospective studies
Yucong Zhang, Gongwei Long, Haojie Shang, Beichen Ding, Guoliang Sun, Wei Ouyang, Man Liu, Yuan Chen, Heng Li, Hua Xu, Zhangqun Ye
Asian Journal of Urology.2021; 8(1): 117. CrossRef
Machine Learning Approach to Predict the Probability of Recurrence of Renal Cell Carcinoma After Surgery: Prediction Model Development Study
HyungMin Kim, Sun Jung Lee, So Jin Park, In Young Choi, Sung-Hoo Hong
JMIR Medical Informatics.2021; 9(3): e25635. CrossRef
Long-term results of surgical treatment for stage cT1 kidney cancer
Sergey A. Rakul, Pavel N. Romashchenko, Kirill V. Pozdnyakov, Nikolay A. Maistrenko
Bulletin of the Russian Military Medical Academy.2021; 23(3): 133. CrossRef
Retroperitoneal laparoscopic partial versus radical nephrectomy for large (≥ 4 cm) and anatomically complex renal tumors: A propensity score matching study
Wen Deng, Zhengtao Zhou, Jian Zhong, Junhua Li, Xiaoqiang Liu, Luyao Chen, Jingyu Zhu, Bin Fu, Gongxian Wang
European Journal of Surgical Oncology.2020; 46(7): 1360. CrossRef
Synchronous sporadic bilateral multiple chromophobe renal cell carcinoma accompanied by a clear cell carcinoma and a cyst: A case report
Fan Yang, Zi-Chen Zhao, A-Jin Hu, Peng-Fei Sun, Bin Zhang, Ming-Chuan Yu, Juan Wang
World Journal of Clinical Cases.2020; 8(14): 3064. CrossRef
Peri‐operative and local control outcomes of robot‐assisted partial nephrectomy vs percutaneous cryoablation for renal masses: comparison after matching on radiological stage and renal score
Guillaume Fraisse, Loïc Colleter, Benoit Peyronnet, Zine‐Eddine Khene, Qusay Mandoorah, Yanish Soorojebally, Ali Bourgi, Alexandre De La Taille, Morgan Roupret, Eric De Kerviler, François Desgrandchamps, Karim Bensalah, Alexandra Masson‐Lecomte
BJU International.2019; 123(4): 632. CrossRef
Organ-sparing procedures in GU cancer: part 1—organ-sparing procedures in renal and adrenal tumors: a systematic review
Raouf Seyam, Mahmoud I. Khalil, Mohamed H. Kamel, Waleed M. Altaweel, Rodney Davis, Nabil K. Bissada
International Urology and Nephrology.2019; 51(3): 377. CrossRef
Comparison of the long-term follow-up and perioperative outcomes of partial nephrectomy and radical nephrectomy for 4 cm to 7 cm renal cell carcinoma: a systematic review and meta-analysis
Yu-Li Jiang, Cheng-Xia Peng, Heng-Zi Wang, Lu-Jie Qian
BMC Urology.2019;[Epub] CrossRef
Partial nephrectomy versus radical nephrectomy for cT2 or greater renal tumors: a systematic review and meta-analysis
Jingdong Li, Yanping Zhang, Zhihai Teng, Zhenwei Han
Minerva Urologica e Nefrologica.2019;[Epub] CrossRef
Analysis of survival for patients with chronic kidney disease primarily related to renal cancer surgery
Jitao Wu, Chalairat Suk‐Ouichai, Wen Dong, Elvis Caraballo Antonio, Ithaar H. Derweesh, Brian R. Lane, Sevag Demirjian, Jianbo Li, Steven C. Campbell
BJU International.2018; 121(1): 93. CrossRef
Oncologic Outcomes of Partial Nephrectomy for Stage T3a Renal Cell Cancer
Asaf Shvero, Ofer Nativ, Yasmin Abu-Ghanem, Dorit Zilberman, Bahouth Zaher, Max Levitt, Eddie Fridman, Orith Portnoy, Jacob Ramon, Zohar A. Dotan
Clinical Genitourinary Cancer.2018; 16(3): e613. CrossRef
External Validation of Contact Surface Area as a Predictor of Postoperative Renal Function in Patients Undergoing Partial Nephrectomy
Miki Haifler, Benjamin T. Ristau, Andrew M. Higgins, Marc C. Smaldone, Alexander Kutikov, Amnon Zisman, Robert G. Uzzo
Journal of Urology.2018; 199(3): 649. CrossRef
Survival outcomes in patients with large (≥7cm) clear cell renal cell carcinomas treated with nephron-sparing surgery versus radical nephrectomy: Results of a multicenter cohort with long-term follow-up
M. W. W. Janssen, J. Linxweiler, S. Terwey, S. Rugge, C.-H. Ohlmann, F. Becker, Ch. Thomas, A. Neisius, J. W. Thüroff, S. Siemer, M. Stöckle, F. C. Roos, Christian Schwentner
PLOS ONE.2018; 13(5): e0196427. CrossRef
Radiofrequency ablation versus cryoablation for T1b renal cell carcinoma: a multi-center study
Takaaki Hasegawa, Takashi Yamanaka, Hideo Gobara, Masaya Miyazaki, Haruyuki Takaki, Yozo Sato, Yoshitaka Inaba, Koichiro Yamakado
Japanese Journal of Radiology.2018; 36(9): 551. CrossRef
Néphrectomie partielle pour tumeur de plus de 7 cm : morbidité, résultats oncologiques et fonctionnels (UroCCR-7 study)
J. Rouffilange, A. Gobet, G. Capon, V. Comat, S. Lagabrielle, A. Guillaume, G. Robert, H. Bensadoun, J.-M. Ferrière, J.-C. Bernhard
Progrès en Urologie.2018; 28(12): 588. CrossRef
Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies
Maria Carmen Mir, Ithaar Derweesh, Francesco Porpiglia, Homayoun Zargar, Alexandre Mottrie, Riccardo Autorino
European Urology.2017; 71(4): 606. CrossRef
Utilization trends and outcomes up to 3 months of open, laparoscopic, and robotic partial nephrectomy
Jamie S. Pak, Jason J. Lee, Khawaja Bilal, Mark Finkelstein, Michael A. Palese
Journal of Robotic Surgery.2017; 11(2): 223. CrossRef
Early surgical outcomes and oncological results of robot‐assisted partial nephrectomy: a multicentre study
Rajan Veeratterapillay, Sanjai K. Addla, Clare Jelley, John Bailie, David Rix, Steve Bromage, Neil Oakley, Robin Weston, Naeem A. Soomro
BJU International.2017; 120(4): 550. CrossRef
External validation of the Arterial Based Complexity (ABC) scoring system in renal tumors treated by minimally invasive partial nephrectomy
Liangyou Gu, Xin Ma, Hongzhao Li, Yuanxin Yao, Yongpeng Xie, Luyao Chen, Yu Gao, Xu Zhang
Journal of Surgical Oncology.2017; 116(4): 507. CrossRef
Partial nephrectomy vs. radical nephrectomy for renal tumors: A meta-analysis of renal function and cardiovascular outcomes
Zheng Wang, Ganggang Wang, Qinghua Xia, Zhenhua Shang, Xiao Yu, Muwen Wang, Xunbo Jin
Urologic Oncology: Seminars and Original Investigations.2016; 34(12): 533.e11. CrossRef
Novel Use of Folate-Targeted Intraoperative Fluorescence, OTL38, in Robot-Assisted Laparoscopic Partial Nephrectomy: Report of the First Three Cases
Cheuk Fan Shum, Clinton D. Bahler, Philip S. Low, Timothy L. Ratliff, Steven V. Kheyfets, Jay P. Natarajan, George E. Sandusky, Chandru P. Sundaram
Journal of Endourology Case Reports.2016; 2(1): 189. CrossRef
Recommandations en onco-urologie 2016-2018 du CCAFU : Cancer du rein
K. Bensalah, L. Albiges, J.-C. Bernhard, P. Bigot, T. Bodin, R. Boissier, J.-M. Corréas, P. Gimel, J.-A. Long, F.-X. Nouhaud, I. Ouzaïd, P. Paparel, N. Rioux-Leclercq, A. Méjean
Progrès en Urologie.2016; 27: S27. CrossRef

13,966 View
187 Download
35 Web of Science
33 Crossref

Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment: Jung Hyun Lee, Sung Gu Kang, Seung Tae Kim, Seok Ho Kang, In Keun Choi, Young Je Park, Sang Chul Oh, Deuk Jae Sung, Jae Hong Seo, Jun Cheon, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim, Kyong Hwa Park; Cancer Res Treat. 2014;46(2):172-177. Published online April 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.2.172

Abstract PDF PubReader ePub

Purpose

There is no established standard second-line chemotherapy for patients with advanced or metastatic urothelial carcinoma (UC) who failed gemcitabine and cisplatin (GC) chemotherapy. This study was conducted in order to investigate the efficacy and toxicity of modified methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) in patients with metastatic UC previously treated with GC.

Materials and Methods

We retrospectively analyzed 28 patients who received modified MVAC between November 2004 and November 2012. All patients failed prior, first-line GC chemotherapy.

Results

The median age of patients was 64.0 years (range, 33.0 to 77.0 years), and 23 (82.1%) patients had an Eastern Cooperative Oncology Group performance status of 0 or 1. The overall response rate and the disease control rate were 36.0% and 64.0%, respectively. After a median follow-up period of 38 weeks (range, 5 to 182 weeks), median progression free survival was 21.0 weeks (95% confidence interval [CI], 6.3 to 35.7 weeks) and median overall survival was 49.0 weeks (95% CI, 18.8 to 79.3 weeks). Grade 3 or 4 hematological toxicities included neutropenia (n=21, 75.0%) and anemia (n=9, 32.1%). Grade 3 or 4 non-hematological toxicities did not occur and there was no treatment-related death.

Conclusion

Modified MVAC appears to be a safe and active chemotherapy regimen in patients with stable physical status and adequate renal function after GC treatment.

Citations

Citations to this article as recorded by

Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis
Teruki Isobe, Taku Naiki, Yosuke Sugiyama, Aya Naiki-Ito, Takashi Nagai, Toshiki Etani, Satoshi Nozaki, Keitaro Iida, Yusuke Noda, Nobuhiko Shimizu, Nami Tomiyama, Rika Banno, Hiroki Kubota, Shuzo Hamamoto, Ryosuke Ando, Noriyasu Kawai, Takahiro Yasui
International Journal of Clinical Oncology.2022; 27(1): 165. CrossRef
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer
Axel S. Merseburger, Andrea B. Apolo, Simon Chowdhury, Noah M. Hahn, Matthew D. Galsky, Matthew I. Milowsky, Daniel Petrylak, Tom Powles, David I. Quinn, Jonathan E. Rosenberg, Arlene Siefker-Radtke, Guru Sonpavde, Cora N. Sternberg
World Journal of Urology.2019; 37(1): 95. CrossRef
Efficacy of Different Second-line Therapy Regimens in Metastatic Urothelial Carcinoma
Lukas Barwitz, Anne Berger, Stefanie Zschaebitz, Max Jenzer, Cathleen Nientiedt, Stefan Duensing, Dirk Jäger, Dogu Teber, Markus Hohenfellner, Carsten Grüllich
The Open Urology & Nephrology Journal.2017; 10(1): 52. CrossRef
Cisplatin- Versus Non–Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin
Jennifer A. Locke, Gregory Russell Pond, Guru Sonpavde, Andrea Necchi, Patrizia Giannatempo, Ravi Kumar Paluri, Guenter Niegisch, Peter Albers, Carlo Buonerba, Giuseppe Di Lorenzo, Ulka N. Vaishampayan, Scott A. North, Neeraj Agarwal, Syed A. Hussain, Sum
Clinical Genitourinary Cancer.2016; 14(4): 331. CrossRef
Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond—A Comprehensive Review of the Current Literature
Christoph Oing, Michael Rink, Karin Oechsle, Christoph Seidel, Gunhild von Amsberg, Carsten Bokemeyer
Journal of Urology.2016; 195(2): 254. CrossRef
Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP)
Ki Hong Kim, Sung Joon Hong, Kyung Seok Han
BMC Cancer.2015;[Epub] CrossRef

12,724 View
91 Download
6 Web of Science
6 Crossref

Biopsy Related Prostate Status Does Not Affect on the Clinicopathological Outcome of Robotic Assisted Laparoscopic Radical Prostatectomy: Hoon Choi, Young Hwii Ko, Sung Gu Kang, Seok Ho Kang, Hong Seok Park, Jun Cheon, Vipul R. Patel; Cancer Res Treat. 2009;41(4):205-210. Published online December 31, 2009; DOI: https://doi.org/10.4143/crt.2009.41.4.205

Abstract PDF PubReader ePub

Purpose

To determine whether the biopsy core number and time interval between prostate biopsy and radical prostatectomy affect the operative and oncologic outcome of robot assisted laparoscopic radical prostatectomy (RALP).

Materials and Methods

From January 2008 to April 2009, a single surgeon performed 72 RALPs after an initial learning period of 30 cases. The relationship between time from biopsy to prostatectomy and biopsy core number with operative time and estimated blood loss (EBL) were initially evaluated with a linear regression model. These patients were classified into groups according to whether the interval from biopsy to RALP was within four weeks or not, and whether there were less than or greater than 10 core specimens removed.

Results

RALP was performed in 34 patients within four weeks of biopsy, and in 38 patients more than 4 weeks after biopsy. According to the number of core specimens removed, less than 10 cores were performed in 10 patients, and more than 10 cores were performed in 62 patients. Using an interval of 4 weeks as the cutoff point, early surgery was associated with longer operating time (232.6 vs 208.8 min) and increased estimated blood loss (305.1 vs 276.9 mL). For cases with more than 10 biopsy cores, there was a slight increase in operative time (229.2 vs 210.3 min). None of these differences were statistically significant by multivariate analysis.

Conclusion

Our data suggests that there is no reason to delay RALP to more than 4 weeks after prostate biopsy. It also revealed that the number of biopsy cores (up to 14) did not influence operative outcome. Thus, RALP is a feasible procedure regardless of the biopsy related prostate state.

Citations

Citations to this article as recorded by

Effect of Transperineal Versus Transrectal Prostate Biopsy on the Quality of Hydrogel Spacer Placement in Men Prior to Radiation Therapy for Prostate Cancer
Michael E. Rezaee, Ulysses Gardner, Mark N. Alshak, Stephen C. Greco, Daniel Y. Song, Michael Goldstein, Christian P. Pavlovich
Urology.2023; 182: 27. CrossRef
Does time interval between prostate biopsy and surgery affect outcomes of radical prostatectomy? A systematic review and meta-analysis
Jie Li, Qing Jiang, Qiubo Li, Yuanfeng Zhang, Liang Gao
International Urology and Nephrology.2020; 52(4): 619. CrossRef
Short interval of biopsy to robotic-assisted laparoscopic radical prostatectomy does not render any adverse effects on the perioperative outcomes
Minke He, Yaohui Li, Zhuoyi Xiang, Li-an Sun, Yanjun Zhu, Xiaoyi Hu, Jianming Guo, Hang Wang
Medicine.2018; 97(36): e11686. CrossRef
A Multidimensional Analysis of Prostate Surgery Costs in the United States: Robotic-Assisted versus Retropubic Radical Prostatectomy
Akash Bijlani, April E. Hebert, Mike Davitian, Holly May, Mark Speers, Robert Leung, Nihal E. Mohamed, Henry S. Sacks, Ashutosh Tewari
Value in Health.2016; 19(4): 391. CrossRef
Interval from Prostate Biopsy to Radical Prostatectomy Does Not Affect Immediate Operative Outcomes for Open or Minimally Invasive Approach
Bumsoo Park, Seol Ho Choo, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi
Journal of Korean Medical Science.2014; 29(12): 1688. CrossRef
Interval from Prostate Biopsy to Robot-Assisted Laparoscopic Radical Prostatectomy (RALP): Effects on Surgical Difficulties
In Sung Kim, Woong Na, Jung Su Nam, Jong Jin Oh, Chang Wook Jeong, Sung Kyu Hong, Seok Soo Byun, Sang Eun Lee
Korean Journal of Urology.2011; 52(10): 664. CrossRef
Prostate-Specific Antigen Density as a Powerful Predictor of Extracapsular Extension and Positive Surgical Margin in Radical Prostatectomy Patients with Prostate-Specific Antigen Levels of Less than 10 ng/ml
Jin-Seok Chang, Hoon Choi, Young-Seop Chang, Jin-Bum Kim, Mi Mi Oh, Du Geon Moon, Jae Hyun Bae, Jun Cheon
Korean Journal of Urology.2011; 52(12): 809. CrossRef

9,620 View
51 Download
7 Crossref

A Matched-cohort Comparison of Laparoscopic Renal Cryoablation using Ultra-thin Cryoprobes with Open Partial Nephrectomy for the Treatment of Small Renal Cell Carcinoma: Young Hwii Ko, Hong Seok Park, Du Geon Moon, Jeong Gu Lee, Je Jong Kim, Duck Ki Yoon, Seok Ho Kang, Jun Cheon; Cancer Res Treat. 2008;40(4):184-189. Published online December 31, 2008; DOI: https://doi.org/10.4143/crt.2008.40.4.184

Abstract PDF PubReader ePub

Purpose

To evaluate the feasibility and efficacy of performing laparoscopic renal cryoablation (LRC) for the treatment of RCC, as compared with open partial nephrectomy (OPN), which is the established NSS.

Materials and Methods

From April 2004, among the patients who underwent LRC with a 1.47 mm cryoprobe, we enrolled 20 patients who were pathologically confirmed as having RCC with a tumor size smaller than 4 cm. These patients were matched with a group of 20 patients, who were selected based on the pre-operative characteristics of the tumor and those of the patients, from a pre-existing database of the patients who underwent OPN during the same period.

Results

The mean age and tumor size were 56.3±11.5 years and 2.4±1.7 cm in the LRC group, and 57.6±10.9 years and 2.2±1.1 cm in the OPN group. The two groups were similar for their age, gender, BMI, ASA, the tumor characteristics and the indications for operation. While the pathologic results and the operation time showed similarity, the EBL (98±87 ml vs 351±147 ml, respectively, p=0.001), the transfusion rate (10% vs 40%, respectively, p=0.03) and the hospital stay (4.2±1.5 days vs 8.2±2.4 days, respectively, p=0.005) were significantly less in the LRC group. Major complications did not occur in the LRC group, but in the OPN group, one patient experienced urine leakage and one patient had a perirenal hematoma. During the mean follow up of 27.3±10.8 months and 28.7±14.9 months for each group, respectively, all the patients remained disease-free with no evidence of local recurrence or metastases.

Conclusions

LRC using ultra-thin cryoprobes for the treatment of small RCC showed similar effective oncologic results with the merits of minimal invasiveness, as compared with OPN, during the intermediate term follow up.

Citations

Citations to this article as recorded by

Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis
Ryan S Huang, Ronald Chow, Ali Benour, David Chen, Gabriel Boldt, Christopher J D Wallis, Anand Swaminath, Charles B Simone, Michael Lock, Srinivas Raman
The Lancet Oncology.2025; 26(3): 387. CrossRef
Stage IA papillary and chromophobe renal cell carcinoma: effectiveness of cryoablation and partial nephrectomy
Annemarie Uhlig, Johannes Uhlig, Brian Shuch, Hyun S. Kim
Insights into Imaging.2024;[Epub] CrossRef
Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis
Takafumi Yanagisawa, Keiichiro Mori, Tatsushi Kawada, Reza Sari Motlagh, Hadi Mostafaei, Fahad Quhal, Ekaterina Laukhtina, Pawel Rajwa, Abdulmajeed Aydh, Frederik König, Maximilian Pallauf, Benjamin Pradere, Jun Miki, Takahiro Kimura, Shin Egawa, Shahrokh
Urologic Oncology: Seminars and Original Investigations.2022; 40(7): 315. CrossRef
Partial nephrectomy vs cryoablation for T1a renal cell carcinoma: A comparison of survival benefit stratified by tumour size
Xinyang Liao, Shi Qiu, Wanyu Wang, Xiaonan Zheng, Kun Jin, Shiyu Zhang, Yige Bao, Lu Yang, Qiang Wei
Cancer Epidemiology.2019; 59: 221. CrossRef
Partial nephrectomy versus ablative therapies for cT1a renal masses: A Systematic Review and meta-analysis
Xu Hu, Yan-Xiang Shao, Yan Wang, Zhi-Qiang Yang, Wei-Xiao Yang, Xiang Li
European Journal of Surgical Oncology.2019; 45(9): 1527. CrossRef
Comparison among cryoablation, radiofrequency ablation, and partial nephrectomy for renal cell carcinomas sized smaller than 2 cm or sized 2–4 cm
Shuai Yan, Wei Yang, Cheng-mei Zhu, Pei-meng Yan, Zhi-chao Wang
Medicine.2019; 98(21): e15610. CrossRef
Ablative Therapy for Small Renal Masses
Benjamin L. Taylor, S. William Stavropoulos, Thomas J. Guzzo
Urologic Clinics of North America.2017; 44(2): 223. CrossRef
A national study of kidney graft tumor treatments: Toward ablative therapy
Kerem Guleryuz, Arnaud Doerfler, Ricardo Codas, Grégoire Coffin, Jacques Hubert, Eric Lechevallier, Xavier Tillou, L. Badet, B. Barrou, T. Bessede, P. Blanchet, J.M. Boutin, J. Branchereau, T. Culty, V. Delaporte, F. Gaudez, M. Gigante, G. Karam, F. Klein
Surgery.2016; 160(1): 237. CrossRef
Guía de manejo del carcinoma de células renales
William Quiroga Matamoros, Fernando Fernandez, Danilo Citarella Otero, Jaime Rangel, Andrea Estrada Guerrero, Iván Darío Patiño
Urología Colombiana.2016; 25(2): 169. CrossRef
Current Status of Cryotherapy for Prostate and Kidney Cancer
Seok Cho, Seok Ho Kang
Korean Journal of Urology.2014; 55(12): 780. CrossRef
Retrospective Comparison of Laparoscopic Partial Nephrectomy Versus Laparoscopic Renal Cryoablation for Small (<3.5 cm) Cortical Renal Masses
Georgios Haramis, Joseph A. Graversen, Adam C. Mues, Ruslan Korets, Juan Carlos Rosales, Zhamshid Okhunov, Ketan K. Badani, Mantu Gupta, Jaime Landman
Journal of Laparoendoscopic & Advanced Surgical Techniques.2012; 22(2): 152. CrossRef
Systematic Review of Perioperative and Quality-of-life Outcomes Following Surgical Management of Localised Renal Cancer
Steven MacLennan, Mari Imamura, Marie C. Lapitan, Muhammad Imran Omar, Thomas B.L. Lam, Ana M. Hilvano-Cabungcal, Pam Royle, Fiona Stewart, Graeme MacLennan, Sara J. MacLennan, Philipp Dahm, Steven E. Canfield, Sam McClinton, T.R. Leyshon Griffiths, Börje
European Urology.2012; 62(6): 1097. CrossRef
Systematic Review of Oncological Outcomes Following Surgical Management of Localised Renal Cancer
Steven MacLennan, Mari Imamura, Marie C. Lapitan, Muhammad Imran Omar, Thomas B.L. Lam, Ana M. Hilvano-Cabungcal, Pam Royle, Fiona Stewart, Graeme MacLennan, Sara J. MacLennan, Steven E. Canfield, Sam McClinton, T.R. Leyshon Griffiths, Börje Ljungberg, Ja
European Urology.2012; 61(5): 972. CrossRef
Perioperative, Oncologic, and Functional Outcomes of Laparoscopic Renal Cryoablation and Open Partial Nephrectomy: A Matched Pair Analysis
Tobias Klatte, Julian Mauermann, Gertraud Heinz-Peer, Matthias Waldert, Peter Weibl, Hans Christoph Klingler, Mesut Remzi
Journal of Endourology.2011; 25(6): 991. CrossRef

9,576 View
81 Download
14 Crossref

A Clinical Trial on the BTA (Bladder Tumor Antigen) Test for Monitoring and Diagnosis of Bladder Transitional Cell Carcinoma: Eun Young Choi, Je Jong Kim, Jun Cheon; J Korean Cancer Assoc. 1999;31(3):556-561.

Abstract PDF: No abstract available.

2,413 View
14 Download

First
Prev
Page of 1
Next
Last

Search